期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

上皮性卵巢癌免疫治疗的研究进展 被引量：2

在线阅读 下载PDF
导出
摘要 卵巢恶性肿瘤的发病率近40年来增加了2～3倍并有逐步上升的趋势,根据美国癌症协会2007年的报道,22430例新诊断的卵巢癌病例中约有15280例死亡。约90％的卵巢恶性肿瘤为上皮性卵巢癌，其死亡率仍高居妇科恶性肿瘤死亡率之首，并位于妇女死亡原因第五位，严重威胁着妇女的生命和健康。
作者 刘婵桢 昌晓红 崔恒
机构地区 北京大学人民医院妇科肿瘤中心 北京大学人民医院妇产科
出处 《中国医药生物技术》 CSCD 2010年第1期53-56,共4页 Chinese Medicinal Biotechnology
基金 国家自然科学基金(30772320)
关键词 上皮性卵巢癌 免疫治疗 卵巢恶性肿瘤 肿瘤死亡率 死亡原因 发病率 妇女
分类号 R737.31 [医药卫生—肿瘤] R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin, 2007, 57(1):43-66.
  • 2Herrin VE, Achtar MS, Steinberg SM, et al. A randomized phase Ⅱ p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients//ASCO Annual Meeting, Chicago, 2007. Alexandria, USA: Journal of Clinical Oncology, 2007, 25(18):3011.
  • 3Leffers N, Lambeck AJ, Gooden MJ, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase Ⅱ trial. Int J Cance, 2009, 125(9):2104-2113.
  • 4Koido S, Nikrui N, Ohana M, et al. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol, 2005, 99(2):462-471.
  • 5Reinartz S, Kohler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ⅰb/Ⅱ). Clin Cancer Res, 2004, 10(5):1580-1587.
  • 6Pfisterer J, du Bois A, Sehouli J, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase Ⅰ trial of the AGO-OVAR. Ann Oncol, 2006, 17(10):1568-1577.
  • 7Datamonitor's business. Monoclonal Antibodies Update DMHC2427. (2008-06-06)[2009-05-02]. http://www.market-research-report.com/ datamonitor/DMHC2427.htm.
  • 8Method MW, Gordon AN, Finkler N, et al. Final Analysis of a Randomized Dosing Study of oregovomab in Patients With Advanced Ovarian Cancer//ASCO Annual Meeting, Orlando, 2005. Alexandria, USA: Journal of Clinical Oncology, 2005, 23(16):5035.
  • 9Berek JS, Taylor PT, Nicodemus CE CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother, 2008, 31(2):207-214.
  • 10Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol, 2009, 27(3):418-425.

二级参考文献12

共引文献58

同被引文献19

  • 1Kryczek,I.,S.Wei,G.Zhu,et al.Relationship between B7-H4,regulatory T cells,and patient outcome in human ovarian carcinoma.Cancer Res,2007,67(18):8900-8905.
  • 2Wolf,D.,A.M.Wolf,H.Rumpold,et al.The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.Clin Cancer Res,2005,11(23):8326-8331.
  • 3Barnett,J.C.,S.M.Bean,R.S.Whitoker,et al.Ovarian cancer tumor infiltrating T-regulatory(T(reg))cells are associated with a metastatic phenotype.Gynecol Oncol,116(3):556-562.
  • 4Wei,S.,I.Kryczek,R.P.Edwards,et al.Interleukin-2 aclministration alters the CD4+FOXP3+T-cell pool and tumor trafficking in patients with ovarian carcinoma.Cancer Res,2007,67(15):7487-7494.
  • 5Nizar,S.,J.Copier,B.Meyer,et al.T-regulatory cell modulation:the future of cancer immunotherapy? Br J Cancer,2009,100(11):1697-1703.
  • 6Hodi,F.S.,M.C.Mihm,R.J.Soiffer,et al.Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.Proc Natl Acad Sci U S A,2003,100(8):4712-4717.
  • 7Kandalaft,L.E.,N:Singh,J.B.Liao,et al.The emergence of immunomedulation:combinatorial immunochemotherapy opportunities for the next decade.Gynecol Oncol,116(2):222-233.
  • 8Curiel,T.J.,Regulatory T cells and treatment of cancer.Curr Opin Immunol,2008,20(2):241-246.
  • 9Liu,B.,J.Nash,C.Runowicz,et al.Ovarian cancer immunotherapy:opportunities,progresses and challenges.J Hematol Oncol,3:7.
  • 10Barnett,B.,I.Kryczek,P.Cheng,et al.Regulatory T cells in ovarian cancer:biology and therapeutic potential.Am J Reprod Immunol,2005,54(6):369-377.

引证文献2

二级引证文献15

中国医药生物技术
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部